A TLR4-interacting SPA4 peptide inhibits LPS-induced lung inflammation

Innate Immunity

Volumn 19, Issue 6, 2013, Pages 596-610

  Ramani, Vijay ^a   Madhusoodhanan, Rakhesh ^a   Kosanke, Stanley ^b   Awasthi, Shanjana ^a  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

host defense; Inflammation; protein protein interaction; surfactant protein A; Toll like receptor 4

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; LUCIFERASE; PLASMID DNA; SURFACTANT PROTEIN A; SURFACTANT PROTEIN A4; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DENDRITIC CELL; EMBRYO; ENZYME ACTIVITY; ESCHERICHIA COLI; FEMALE; GENETIC TRANSFECTION; HOST RESISTANCE; HUMAN; HUMAN CELL; LEUKOCYTE; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PNEUMONIA; PROTEIN PROTEIN INTERACTION; SEPTIC SHOCK; TWO HYBRID SYSTEM;

HOST DEFENSE; INFLAMMATION; PROTEIN-PROTEIN INTERACTION; SURFACTANT PROTEIN-A; TOLL-LIKE RECEPTOR-4;

AMINO ACID SEQUENCE; ANIMALS; DENDRITIC CELLS; FEMALE; HEK293 CELLS; HUMANS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE FRAGMENTS; PNEUMONIA; PROTEIN BINDING; PROTEIN INTERACTION MAPS; PULMONARY SURFACTANT-ASSOCIATED PROTEIN A; SHOCK, SEPTIC; TOLL-LIKE RECEPTOR 4; TRANSGENES;

EID: 84887923682     PISSN: 17534259     EISSN: 17534267     Source Type: Journal    
DOI: 10.1177/1753425912474851     Document Type: Article

References (55)

1. Sheu CC, Gong MN, Zhai R, Chen F, Bajwa EK, Clardy PF, et al. Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS. Chest. 2010 ; 138: 559-567
2. Andrews P, Azoulay E, Antonelli M, Brochard L, Brun-Buisson C, De Backer D, et al. Year in review in Intensive Care Medicine, 2006. II. Infections and sepsis, haemodynamics, elderly, invasive and noninvasive mechanical ventilation, weaning, ARDS. Intensive Care Med. 2007 ; 33: 214-229
3. Yamashita CM, Lewis JF. Emerging therapies for treatment of acute lung injury and acute respiratory distress syndrome. Expert Opin Emerg Drugs. 2012 ; 17: 1-4
4. delsesto D, Opal SM Sepsis - pro-inflammatory and anti-inflammatory responses. Egesten H, ed. Basel: Karger ; 2011: 137-156.
5. Khilnani GC, Hadda V. Corticosteroids and ARDS: A review of treatment and prevention evidence. Lung India. 2011 ; 28: 114-119
6. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun. 2011 ; 25: 1281-1289
7. Pastva AM, Wright JR, Williams KL. Immunomodulatory roles of surfactant proteins A and D: implications in lung disease. Proc Am Thorac Soc. 2007 ; 4: 252-257
8. Sever-Chroneos Z, Krupa A, Davis J, Hasan M, Yang CH, Szeliga J, et al. Surfactant protein A (SP-A)-mediated clearance of Staphylococcus aureus involves binding of SP-A to the staphylococcal adhesin eap and the macrophage receptors SP-A receptor 210 and scavenger receptor class A. J Biol Chem. 2011 ; 286: 4854-4870
9. Janssen WJ, McPhillips KA, Dickinson MG, Linderman DJ, Morimoto K, Xiao YQ, et al. Surfactant proteins A and D suppress alveolar macrophage phagocytosis via interaction with SIRP alpha. Am J Respir Crit Care Med. 2008 ; 178: 158-167
10. Gupta N, Manevich Y, Kazi AS, Tao JQ, Fisher AB, Bates SR. Identification and characterization of p63 (CKAP4/ERGIC-63/CLIMP-63), a surfactant protein A binding protein, on type II pneumocytes. Am J Physiol Lung Cell Mol Physiol. 2006 ; 291: L436 - L446
11. Yamada C, Sano H, Shimizu T, Mitsuzawa H, Nishitani C, Himi T, et al. Surfactant protein A directly interacts with TLR4 and MD-2 and regulates inflammatory cellular response. Importance of supratrimeric oligomerization. J Biol Chem. 2006 ; 281: 21771-21780
12. Awasthi S, Brown K, King C, Awasthi V, Bondugula R. A toll-like receptor-4-interacting surfactant protein-A-derived peptide suppresses tumor necrosis factor-alpha release from mouse JAWS II dendritic cells. J Pharmacol Exp Ther. 2011 ; 336: 672-681
13. Awasthi S, Madhusoodhanan R, Wolf R. Surfactant protein-A and toll-like receptor-4 modulate immune functions of preterm baboon lung dendritic cell precursor cells. Cell Immunol. 2011 ; 268: 87-96
14. Schilders G, Pruijn GJ. Biochemical studies of the mammalian exosome with intact cells. Methods Enzymol. 2008 ; 448: 211-226
15. Awasthi S, Coalson JJ, Yoder BA, Crouch E, King RJ. Deficiencies in lung surfactant proteins A and D are associated with lung infection in very premature neonatal baboons. Am J Respir Crit Care Med. 2001 ; 163: 389-397
16. Awasthi S, Coalson JJ, Crouch E, Yang F, King RJ. Surfactant proteins A and D in premature baboons with chronic lung injury (Bronchopulmonary dysplasia). Evidence for an inhibition of secretion. Am J Respir Crit Care Med. 1999 ; 160: 942-949
17. White SH and Wimley WC. Hydrophobic interactions of peptides with membrane interfaces. Biochim Biophys Acta 1998; 1376: 339-352.
18. Maupetit J, Derreumaux P, Tuffery P. PEP-FOLD: an online resource for de novo peptide structure prediction. Nucleic Acids Res. 2009 ; 37: W498 - W503
19. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol. 1982 ; 157: 105-132
20. Awasthi S, Awasthi V, Magee DM, Coalson JJ. Efficacy ofAg2/proline- richAgcDNA-transfected dendritic cells in immunization of mice against Coccidioides posadasii. J Immunol. 2005 ; 175: 3900-3906
21. Awasthi S, Cox RA. Transfection of murine dendritic cell line (JAWS II) by a nonviral transfection reagent. Biotechniques. 2003 ; 35: 600-602
22. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell. 1998 ; 2: 253-258
23. Vilekar P, Awasthi S, Natarajan A, Anant S, Awasthi V. EF24 suppresses maturation and inflammatory response in dendritic cells. Int Immunol. 2012 ; 24: 455-464
24. Metkar S, Awasthi S, Denamur E, Kim KS, Gangloff SC, Teichberg S, et al. Role of CD14 in responses to clinical isolates of Escherichia coli: effects of K1 capsule expression. Infect Immun. 2007 ; 75: 5415-5424
25. Schmekel B, Karlsson SE, Linden M, Sundstrom C, Tegner H, Venge P. Myeloperoxidase in human lung lavage. I. A marker of local neutrophil activity. Inflammation. 1990 ; 14: 447-454
26. Wakita K, Tetsu O, McCormick F. A mammalian two-hybrid system for adenomatous polyposis coli-mutated colon cancer therapeutics. Cancer Res. 2001 ; 61: 854-858
27. Cho YY, Yao K, Bode AM, Bergen HR, Madden BJ, Oh SM, et al. RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem. 2007 ; 282: 8380-8392
28. Maruyama A, Nishikawa K, Kawatani Y, Mimura J, Hosoya T, Harada N, et al. The novel Nrf2-interacting factor KAP1 regulates susceptibility to oxidative stress by promoting the Nrf2-mediated cytoprotective response. Biochem J. 2011 ; 436: 387-397
29. Kaisho T, Akira S. Toll-like receptors and their signaling mechanism in innate immunity. Acta Odontol Scand. 2001 ; 59: 124-130
30. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Bioph Res Commun. 2009 ; 388: 621-625
31. LeVine AM, Kurak KE, Wright JR, Watford WT, Bruno MD, Ross GF, et al. Surfactant protein-A binds group B streptococcus enhancing phagocytosis and clearance from lungs of surfactant protein-A-deficient mice. Am J Respir Cell Mol Biol. 1999 ; 20: 279-286
32. Famuyide ME, Hasday JD, Carter HC, Chesko KL, He JR, Viscardi RM. Surfactant protein-A limits Ureaplasma-mediated lung inflammation in a murine pneumonia model. Pediatr Res. 2009 ; 66: 162-167
33. Haczku A. Protective role of the lung collectins surfactant protein A and surfactant protein D in airway inflammation. J Allergy Clin Immunol. 2008 ; 122: 861-879
34. Yang S, Milla C, Panoskaltsis-Mortari A, Ingbar DH, Blazar BR, Haddad IY. Human surfactant protein a suppresses T cell-dependent inflammation and attenuates the manifestations of idiopathic pneumonia syndrome in mice. Am J Respir Cell Mol Biol. 2001 ; 24: 527-536
35. Wright JR, Borron P, Brinker KG, Folz RJ. Surfactant Protein A: regulation of innate and adaptive immune responses in lung inflammation. Am J Respir Cell Mol Biol. 2001 ; 24: 513-517
36. Betsuyaku T, Kuroki Y, Nagai K, Nasuhara Y, Nishimura M. Effects of ageing and smoking on SP-A and SP-D levels in bronchoalveolar lavage fluid. Eur Respir J. 2004 ; 24: 964-970
37. LeVine AM, Hartshorn K, Elliott J, Whitsett J, Korfhagen T. Absence of SP-A modulates innate and adaptive defense responses to pulmonary influenza infection. Am J Physiol Lung Cell Mol Physiol. 2002 ; 282: L563 - L572
38. Atochina EN, Beck JM, Scanlon ST, Preston AM, Beers MF. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J Lab Clin Med. 2001 ; 137: 429-439
39. Pison U, Obertacke U, Seeger W, Hawgood S. Surfactant protein A (SP-A) is decreased in acute parenchymal lung injury associated with polytrauma. Eur J Clin Invest. 1992 ; 22: 712-718
40. Hartshorn KL. Role of surfactant protein A and D (SP-A and SP-D) in human antiviral host defense. Front Biosci (Schol Ed). 2010 ; 2: 527-546
41. Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, et al. By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell. 2003 ; 115: 13-23
42. Awasthi S. Surfactant protein (SP)-A and SP-D as antimicrobial and immunotherapeutic agents. Recent Pat Antiinfect Drug Discov. 2010 ; 5: 115-123
43. Sadowitz B, Roy S, Gatto LA, Habashi N, Nieman G. Lung injury induced by sepsis: lessons learned from large animal models and future directions for treatment. Expert Rev Anti Infect Ther. 2011 ; 9: 1169-1178
44. Haagsman HP, White RT, Schilling J, Lau K, Benson BJ, Golden J, et al. Studies of the structure of lung surfactant protein SP-A. Am J Physiol. 1989 ; 257: L421 - L429
45. Mason RJ, Voelker DR. Regulatory mechanisms of surfactant secretion. Biochim Biophys Acta. 1998 ; 1408: 226-240
46. Madhusoodhanan R, Moriasi C, Ramani V, Anant S, Awasthi S. TLR4-interacting peptide (SPA4) inhibits the lipopolysaccharide-stimulated inflammatory response, migration and invasion of colon cancer SW480 cells. OncoImmunology. 2012 ; 1: 1495-1506
47. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol. 2002 ; 168: 5989-5992
48. Murakami S, Iwaki D, Mitsuzawa H, Sano H, Takahashi H, Voelker DR, et al. Surfactant protein A inhibits peptidoglycan-induced tumor necrosis factor-alpha secretion in U937 cells and alveolar macrophages by direct interaction with toll-like receptor 2. J Biol Chem. 2002 ; 277: 6830-6837
49. Chroneos ZC, Sever-Chroneos Z, Shepherd VL. Pulmonary surfactant: an immunological perspective. Cell Physiol Biochem. 2010 ; 25: 13-26
50. Komara JJ, Perez-Trepichio P, Wiedemann HP. Systemic pharmacologic therapy of ARDS. Respir Care Clin N Am. 1998 ; 4: 739-750
51. Li H, Su X, Yan X, Wasserloos K, Chao W, Kaynar AM, et al. Toll-like receptor 4-myeloid differentiation factor 88 signaling contributes to ventilator-induced lung injury in mice. Anesthesiology. 2010 ; 113: 619-629
52. Villar J, Cabrera N, Casula M, Flores C, Valladares F, Muros M, et al. Mechanical ventilation modulates Toll-like receptor signaling pathway in a sepsis-induced lung injury model. Intensive Care Med. 2010 ; 36: 1049-1057
53. Seki H, Tasaka S, Fukunaga K, Shiraishi Y, Moriyama K, Miyamoto K, et al. Effect of Toll-like receptor 4 inhibitor on LPS-induced lung injury. Inflamm Res. 2010 ; 59: 837-845
54. He Z, Zhu Y, Jiang H. Inhibiting toll-like receptor 4 signaling ameliorates pulmonary fibrosis during acute lung injury induced by lipopolysaccharide: an experimental study. Respir Res. 2009 ; 10: 126-126
55. Bersani I, Speer CP, Kunzmann S. Surfactant proteins A and D in pulmonary diseases of preterm infants. Expert Rev Anti Infect Ther. 2012 ; 10: 573-584